kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
Company profile
Ticker
KALA
Exchange
Website
CEO
Mark Iwicki
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Kala Pharmaceuticals, Inc.
SEC CIK
Corporate docs
Subsidiaries
Kala Pharmaceuticals Security Corporation • Combangio, Inc. ...
KALA stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
19 Apr 24
424B5
Prospectus supplement for primary offering
29 Mar 24
S-8
Registration of securities for employees
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Mar 24
8-K
Entry into a Material Definitive Agreement
26 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Entry into a Material Definitive Agreement
22 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
Transcripts
KALA
Earnings call transcript
2022 Q2
12 Aug 22
KALA
Earnings call transcript
2022 Q1
16 May 22
KALA
Earnings call transcript
2021 Q4
29 Mar 22
KALA
Earnings call transcript
2021 Q3
15 Nov 21
KALA
Earnings call transcript
2021 Q2
5 Aug 21
KALA
Earnings call transcript
2021 Q1
5 May 21
KALA
Earnings call transcript
2020 Q4
25 Feb 21
KALA
Earnings call transcript
2020 Q3
7 Nov 20
KALA
Earnings call transcript
2020 Q3
5 Nov 20
KALA
Earnings call transcript
2020 Q2
8 Aug 20
Latest ownership filings
SC 13G
MILLENNIUM MANAGEMENT LLC
16 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Checkpoint Capital L.P.
14 Feb 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
29 Jan 24
4
Eric Trachtenberg
5 Jan 24
4
Darius Kharabi
5 Jan 24
4
Romulus K Brazzell
5 Jan 24
4
Mark T Iwicki
5 Jan 24
4
Mary Reumuth
5 Jan 24
4
Todd Bazemore
5 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 56.06 mm | 56.06 mm | 56.06 mm | 56.06 mm | 56.06 mm | 56.06 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.92 mm | 3.36 mm | 984.00 k | 2.83 mm |
Cash used (since last report) | n/a | n/a | 19.92 mm | 22.91 mm | 6.71 mm | 19.31 mm |
Cash remaining | n/a | n/a | 36.14 mm | 33.16 mm | 49.35 mm | 36.75 mm |
Runway (months of cash) | n/a | n/a | 12.4 | 9.9 | 50.2 | 13.0 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 1 |
Closed positions | 23 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 44.75 mm |
Total shares | 16.45 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Blumenkranz Mark S. | 5.14 mm | $10.80 mm |
Lagunita | 5.14 mm | $10.80 mm |
Lagunita Biosciences | 5.14 mm | $10.80 mm |
Polaris Venture Partners V | 598.62 k | $2.21 mm |
Checkpoint Capital | 228.03 k | $3.62 mm |
Integrated Core Strategies | 133.70 k | $5.63 mm |
Longitude Capital Partners II | 57.54 k | $884.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Jan 24 | Reumuth Mary | Common Stock | Sell | Dispose S | No | Yes | 6.74 | 1,227 | 8.27 k | 66,136 |
4 Jan 24 | Reumuth Mary | Common Stock | Grant | Acquire A | No | No | 0 | 4,600 | 0.00 | 67,363 |
4 Jan 24 | Reumuth Mary | Stock Option Common Stock | Grant | Acquire A | No | No | 7 | 20,500 | 143.50 k | 20,500 |
4 Jan 24 | Bazemore Todd | Common Stock | Sell | Dispose S | No | Yes | 6.74 | 1,405 | 9.47 k | - |
4 Jan 24 | Bazemore Todd | Common Stock | Grant | Acquire A | No | No | 0 | 6,500 | 0.00 | - |
4 Jan 24 | Bazemore Todd | Stock Option Common Stock | Grant | Acquire A | No | No | 7 | 29,300 | 205.10 k | 29,300 |
4 Jan 24 | Mark T Iwicki | Common Stock | Sell | Dispose S | No | Yes | 6.73 | 4,539 | 30.55 k | 286,315 |
4 Jan 24 | Mark T Iwicki | Common Stock | Grant | Acquire A | No | No | 0 | 14,300 | 0.00 | 290,854 |
4 Jan 24 | Mark T Iwicki | Stock Option Common Stock | Grant | Acquire A | No | No | 7 | 64,500 | 451.50 k | 64,500 |
4 Jan 24 | Darius Kharabi | Common Stock | Sell | Dispose S | No | Yes | 6.73 | 1,385 | 9.32 k | 65,117 |